Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody

Journal of Immunology

Volumn 175, Issue 7, 2005, Pages 4761-4768

  'T Hart, Bert A ^a,b,c   Brok, Herbert P M ^a   Remarque, Ed ^a   Benson, Jacqueline ^d   Treacy, George ^d   Amor, Sandra ^a,c   Hintzen, Rogier Q ^b,c   Laman, Jon D ^b,c   Bauer, Jan ^e   Blezer, Erwin L A ^f  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Multiple Sclerosis Center   (Netherlands)

^d CENTOCOR INC   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYTOKINE; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; INFLAMMATION; MARMOSET; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMATE; PRIORITY JOURNAL; TARGET CELL; TH1 CELL; WHITE MATTER;

EID: 25444476685     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.7.4761     Document Type: Article

References (37)

1. Wang, X., M. Chen, K. P. Wandinger, G. Williams, and S. Dhib-Jalbut. 2000. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J. Immunol. 165: 548-557.
2. Van Boxel-Dezaire, A. H., S. C. Hoff, B. W. van Oosten, C. L. Verweij, A. M. Drager, H. J. Ader, J. C. van Houwelingen, F. Barkhof, C. H. Polman, and L. Nagelkerken. 1999. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45: 695-703.
3. Clerici, M., M. Saresella, D. Trabattoni, L. Speciale, S. Fossati, S. Ruzzante, R. Cavaretta, M. Filippi, D. Caputo, and P. Ferrante. 2001. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 121: 88-101.
4. + monocytes in the blood correlates with the presence of active MRI lesions in MS. J. Neuroimmunol. 119: 145-149.
5. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94: 599-603.
6. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495-521.
7. Byrnes, A. A., J. C. McArthur, and C. L. Karp. 2002. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 51: 165-174.
8. Karp, C. L., A. H. van Boxel-Dezaire, A. A. Byrnes, and L. Nagelkerken. 2001. Interferon-β in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr. Opin. Neurol. 14: 361-368.
9. Karp, C. L., C. A. Biron, and D. N. Irani. 2000. Interferon β in multiple sclerosis: is IL-12 suppression the key? Immunol. Today 21: 24-28.
10. Gran, B., G. X. Zhang, and A. Rostami. 2004. Role of the IL- 12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. 24: 111-128.
11. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
12. Becher, B., B. G. Durell, and R. J. Noelle. 2003. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 112: 1186-1191.
13. Lankford, C. S., and D. M. Frucht. 2003. A unique role for IL-23 in promoting cellular immunity. J. Leukocyte Biol. 73: 49-56.
14. Becher, B., B. G. Durell, and R. J. Noelle. 2002. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110: 493-497.
15. Brok, H. P., J. Bauer, M. Jonker, E. Blezer, S. Amor, R. E. Bontrop, J. D. Laman, and B. A. 't Hart. 2001. Non-human primate models of multiple sclerosis. Immunol. Rev. 183: 173-185.
16. 't Hart, B., S. Amor, and M. Jonker. 2004. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov. Today 9: 517-524.
17. 't Hart, B. A., J. T. Vogels, J. Bauer, H. P. M. Brok, and E. Blezer. 2004. Non-invasive measurement of brain damage in a primate model of multiple sclerosis. Trends Mol. Med. 10: 85-91.
18. Laman, J. D., B. A. 't Hart, H. Brok, M. Meurs, M. M. Schellekens, A. Kasran, L. Boon, J. Bauer, M. Boer, and J. Ceuppens. 2002. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (μ5D12). Eur. J. Immunol. 32: 2218-2228.
19. Boon, L., H. P. Brok, J. Bauer, A. Ortiz-Buijsse, M. M. Schellekens, S. Ramdien-Murli, E. Blezer, M. van Meurs, J. Ceuppens, M. de Boer, et al. 2001. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J. Immunol. 167: 2942-2949.
20. Brok, H. P., M. Van Meurs, E. Blezer, A. Schantz, D. Peritt, G. Treacy, J. D. Laman, J. Bauer, and B. 't Hart. 2002. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol. 169: 6554-6563.
21. 't Hart, B. A., S. D. Laman, J. Bauer, E. D. Blezer, Y. van Kooyk, and R. Q. Hintzen. 2004. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol. 3: 589-597.
22. Hobart, J., N. Kalkers, F. Barkhof, B. Uitdehaag, C. Polman, and A. Thompson. 2004. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult. Scler. 10: 41-46.
23. Molyneux, P. D., G. J. Barker, F. Barkhof, K. Beckmann, F. Dahlke, M. Filippi, M. Ghazi, D. Hahn, D. MacManus, C. Polman, et al. 2001. Clinical-MRI correlations in a European trial of interferon β-1b in secondary progressive MS. Neurology 57: 2191-2197.
24. Traboulsee, A. 2004. MRI: role in optimising treatment. J. Neurol. 251(Suppl. 5): v36-v41.
25. van Walderveen, M. A., F. Barkhof, M. W. Tas, C. Polman, S. T. Frequin, O. R. Hommes, A. J. Thompson, and J. Valk. 1998. Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. Eur. Neurol. 40: 91-98.
26. Morrissey, S. P., H. Stodal, U. Zettl, C. Simonis, S. Jung, R. Kiefer, H. Lassmann, H. P. Hartung, A. Haase, and K. V. Toyka. 1996. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis: quantification of inflammation and oedema. Brain 119: 239-248.
27. Claudio, L., Y. Kress, J. Factor, and C. F. Brosnan. 1990. Mechanisms of edema formation in experimental autoimmune encephalomyelitis: the contribution of inflammatory cells. Am. J. Pathol. 137: 1033-1045.
28. Antunes, S. G., N. G. de Groot, H. Brok, G. Doxiadis, A. A. Menezes, N. Otting, and R. E. Bontrop. 1998. The common marmoset: a new world primate species with limited Mhc class II. variability. Proc. Natl. Acad. Sci. USA 95: 11745-11750.
29. Brok, H. P., A. Uccelli, N. Kerlero De Rosbo, R. E. Bontrop, L. Roccatagliata, N. G. de Groot, E. Capello, J. D. Laman, K. Nicolay, et al. 2000. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J. Immunol. 165: 1093-1101.
30. Brok, H. P., J. M. Tekoppele, J. Hakimi, J. A. Kerwin, E. M. Nijenhuis, C. W. De Groot, R. E. Bontrop, and B. A. 't Hart. 2001. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin. Exp. Immunol. 124: 134-141.
31. 't Hart, B. A., J. D. Laman, J. Bauer, E. Blezer, Y. van Kooyk, and R. Q. Hintzen. 2004. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol. 3: 588-597.
32. 't Hart, B. A., J. Bauer, H. J. Muller, B. Melchers, K. Nicolay, H. Brok, R. E. Bontrop, H. Lassmann, and L. Massacesi. 1998. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am. J. Pathol. 153: 649-663.
33. 't Hart, B. A., M. Losen, H. P. M. Brok, and M. H. de Baets. Chronic Diseases. In The Laboratory Primate. S. P. Wolfe-Coote, ed. Elsevier Science, New York. In press.
34. Stephan, H., G. Baron, and W. K. Schwerdtfeger. 1980. The Brain of the Common Marmoset (Callithrix jacchus): A Stereotactic Atlas. Springer Verlag, Berlin.
35. Kauffman, C. L., N. Aria, E. Toichi, T. S. McCormick, K. D. Cooper, A. B. Gottlieb, D. E. Everitt, B. Frederick, Y. Zhu, M. A. Graham, et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123: 1037-1044.
36. Noseworthy, J. H. 1994. Clinical scoring methods for multiple sclerosis. Ann. Neurol. 36(Suppl.); S80-S85.
37. Sachs, D. H. 2003. Tolerance: of mice and men. J. Clin. Invest. 111: 1819-1821.